vs
Bank First Corp（BFC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Bank First Corp的季度营收约是REGENXBIO Inc.的1.5倍（$44.9M vs $30.3M），Bank First Corp净利率更高（45.8% vs -221.3%，领先267.1%），REGENXBIO Inc.同比增速更快（43.0% vs 12.1%），Bank First Corp自由现金流更多（$51.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 9.1%）
First Horizon Corporation（前身为田纳西第一银行）是一家成立于1864年、总部位于美国田纳西州孟菲斯的金融服务企业。通过旗下子公司First Horizon银行，其业务覆盖美国东南部12个州，是该区域第四大区域性银行。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BFC vs RGNX — 直观对比
营收规模更大
BFC
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出30.9%
12.1%
净利率更高
BFC
高出267.1%
-221.3%
自由现金流更多
BFC
多$103.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $30.3M |
| 净利润 | $18.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 51.0% | -190.0% |
| 净利率 | 45.8% | -221.3% |
| 营收同比 | 12.1% | 43.0% |
| 净利润同比 | 4.8% | -31.2% |
| 每股收益（稀释后） | $1.87 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFCRGNX
| Q4 25 | $44.9M | $30.3M | ||
| Q3 25 | $44.2M | $29.7M | ||
| Q2 25 | $41.6M | $21.4M | ||
| Q1 25 | $43.1M | $89.0M | ||
| Q4 24 | $40.1M | $21.2M | ||
| Q3 24 | $40.8M | $24.2M | ||
| Q2 24 | $38.9M | $22.3M | ||
| Q1 24 | $37.7M | $15.6M |
净利润BFCRGNX
| Q4 25 | $18.4M | $-67.1M | ||
| Q3 25 | $18.0M | $-61.9M | ||
| Q2 25 | $16.9M | $-70.9M | ||
| Q1 25 | $18.2M | $6.1M | ||
| Q4 24 | $17.5M | $-51.2M | ||
| Q3 24 | $16.6M | $-59.6M | ||
| Q2 24 | $16.1M | $-53.0M | ||
| Q1 24 | $15.4M | $-63.3M |
毛利率BFCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BFCRGNX
| Q4 25 | 51.0% | -190.0% | ||
| Q3 25 | 50.8% | -176.3% | ||
| Q2 25 | 49.7% | -296.3% | ||
| Q1 25 | 51.3% | 13.6% | ||
| Q4 24 | 54.4% | -242.1% | ||
| Q3 24 | 50.7% | -256.6% | ||
| Q2 24 | 51.0% | -251.3% | ||
| Q1 24 | 45.6% | -408.8% |
净利率BFCRGNX
| Q4 25 | 45.8% | -221.3% | ||
| Q3 25 | 40.7% | -208.3% | ||
| Q2 25 | 40.5% | -331.8% | ||
| Q1 25 | 42.3% | 6.8% | ||
| Q4 24 | 49.3% | -241.3% | ||
| Q3 24 | 40.6% | -246.3% | ||
| Q2 24 | 41.3% | -237.7% | ||
| Q1 24 | 40.8% | -405.4% |
每股收益（稀释后）BFCRGNX
| Q4 25 | $1.87 | $-1.30 | ||
| Q3 25 | $1.83 | $-1.20 | ||
| Q2 25 | $1.71 | $-1.38 | ||
| Q1 25 | $1.82 | $0.12 | ||
| Q4 24 | $1.75 | $-0.99 | ||
| Q3 24 | $1.65 | $-1.17 | ||
| Q2 24 | $1.59 | $-1.05 | ||
| Q1 24 | $1.51 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $243.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $643.8M | $102.7M |
| 总资产 | $4.5B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BFCRGNX
| Q4 25 | $243.2M | $230.1M | ||
| Q3 25 | $126.2M | $274.2M | ||
| Q2 25 | $120.3M | $323.3M | ||
| Q1 25 | $300.9M | $267.9M | ||
| Q4 24 | $261.3M | $234.7M | ||
| Q3 24 | $204.4M | $255.5M | ||
| Q2 24 | $99.0M | $290.4M | ||
| Q1 24 | $83.4M | $338.7M |
股东权益BFCRGNX
| Q4 25 | $643.8M | $102.7M | ||
| Q3 25 | $628.1M | $161.5M | ||
| Q2 25 | $612.3M | $213.7M | ||
| Q1 25 | $648.4M | $274.2M | ||
| Q4 24 | $639.7M | $259.7M | ||
| Q3 24 | $628.9M | $301.4M | ||
| Q2 24 | $614.6M | $348.3M | ||
| Q1 24 | $609.3M | $390.7M |
总资产BFCRGNX
| Q4 25 | $4.5B | $453.0M | ||
| Q3 25 | $4.4B | $525.2M | ||
| Q2 25 | $4.4B | $581.0M | ||
| Q1 25 | $4.5B | $490.9M | ||
| Q4 24 | $4.5B | $466.0M | ||
| Q3 24 | $4.3B | $519.1M | ||
| Q2 24 | $4.1B | $569.4M | ||
| Q1 24 | $4.1B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $51.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 113.6% | -174.0% |
| 资本支出强度资本支出/营收 | 25.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.40× | — |
| 过去12个月自由现金流最近4个季度 | $75.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BFCRGNX
| Q4 25 | $62.5M | $-52.3M | ||
| Q3 25 | $15.5M | $-56.0M | ||
| Q2 25 | $11.9M | $-49.3M | ||
| Q1 25 | $6.2M | $33.6M | ||
| Q4 24 | $65.8M | $-31.6M | ||
| Q3 24 | $18.8M | $-40.5M | ||
| Q2 24 | $14.9M | $-45.5M | ||
| Q1 24 | $1.3M | $-55.5M |
自由现金流BFCRGNX
| Q4 25 | $51.0M | $-52.8M | ||
| Q3 25 | $12.5M | $-56.5M | ||
| Q2 25 | $8.2M | $-49.7M | ||
| Q1 25 | $4.0M | $32.6M | ||
| Q4 24 | $58.6M | $-32.7M | ||
| Q3 24 | $16.9M | $-40.9M | ||
| Q2 24 | $13.7M | $-46.0M | ||
| Q1 24 | $551.0K | $-56.0M |
自由现金流率BFCRGNX
| Q4 25 | 113.6% | -174.0% | ||
| Q3 25 | 28.2% | -189.9% | ||
| Q2 25 | 19.8% | -232.8% | ||
| Q1 25 | 9.3% | 36.6% | ||
| Q4 24 | 146.3% | -154.2% | ||
| Q3 24 | 41.5% | -168.9% | ||
| Q2 24 | 35.3% | -206.2% | ||
| Q1 24 | 1.5% | -358.5% |
资本支出强度BFCRGNX
| Q4 25 | 25.5% | 1.7% | ||
| Q3 25 | 6.7% | 1.7% | ||
| Q2 25 | 8.7% | 1.8% | ||
| Q1 25 | 5.0% | 1.2% | ||
| Q4 24 | 18.0% | 5.1% | ||
| Q3 24 | 4.5% | 1.3% | ||
| Q2 24 | 3.1% | 2.1% | ||
| Q1 24 | 2.1% | 3.6% |
现金转化率BFCRGNX
| Q4 25 | 3.40× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.34× | 5.53× | ||
| Q4 24 | 3.75× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 0.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
